Skip to main content
OpenTrials
Completed

NCT Number: NCT06380478

Safety and Efficacy of the Bi-Aspheric Monofocal IOL

This is an observational, single-center, non-control, open-label post-marketing study. Patients implanted with an aspicio™ Monofocal Intraocular Lens will be scheduled for a follow-up visit at least 3 months after the surgery to undergo a routine basic ophthalmological examination.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Chang Gung University Hospital

Taoyuan, Guishan District, 333, Taiwan

About this study

This is an observational, single-center, non-control, open-label post-marketing study. Patients implanted with an aspicio™ Monofocal Intraocular Lens will be scheduled for a single visit in the facilities of Chang Gung University Hospital at least 3 months after the surgery. Patients will undergo a routine basic ophthalmological examination.

Additionally, and retrospectively, the patients' medical records will be reviewed to obtain information on visual acuity and adverse events at postoperative visit carried out 1 month after surgery.

The data corresponding to the preoperative values of corneal curvature (flat meridian, curved meridian and axes), axial length measured by biometry, visual acuity and those corresponding to the implanted IOL will also be collected from the medical records.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects 18 years of age or older who have been implanted with aspicio™ monofocal intraocular lens in at least 1 eye
  • Willingness to cooperate with and complete all post-operative visits
  • Ability to comprehend and sign an informed consent

Exclusion criteria

  • Any pathology that could reduce Visual Acuity (VA) (including amblyopia, severe corneal dystrophy, diabetic retinopathy, extremely narrow anterior chamber depth, microphthalmos, clinically significant macular/RPE changes, retinal detachment, corneal transplant, chronic sever uveitis, choroidal hemorrhage, recurrent severe inflammation of the anterior or posterior segment of unknown etiology, iris neovascularization, medically controlled or uncontrolled glaucoma, clinically significant macular degeneration, or diagnosis of pseudoexfoliation).
  • Previous ocular surgery (including YAG-laser) or trauma
  • Clinically significant irregular astigmatism
  • Concomitant severe eye disease
  • Pregnant or lactating
  • Any other ocular or systemic condition which, in the opinion of the investigator, should exclude the subject from the study
  • Concurrent participation in another drug or device investigation
  • May be expected to require other ocular surgery during the study

Treatment and study plan

aspicio Monofocal IOL

Device

A bi-aspheric monofocal IOL is implanted through preloaded IOL Delivery System in the capsular bag in the posterior chamber of the eye during cataract surgery

Other names: aspicio Monofocal, Asqelio Monofocal, ASPP60Y, ASP60Y, QPIO103Y, QLIO103Y

Primary outcomes

  1. CDVA

    Time frame: 3 months after implantation

    Photopic monocular best corrected distance visual acuity (CDVA), 400cm

  2. Defocus curve

    Time frame: 3 months after implantation

    Photopic monocular defocus curve, -4.0 D ~ +2.0 D

Secondary outcomes

  1. UDVA

    Time frame: 3 months after implantation

    Photopic monocular uncorrected distance visual acuity (UDVA), 400cm

  2. UIVA

    Time frame: 3 months after implantation

    Photopic monocular uncorrected intermediate visual acuity (UIVA), 60cm

  3. CIVA

    Time frame: 3 months after implantation

    Photopic monocular corrected intermediate visual acuity (CIVA), 60cm

  4. IOL glistening

    Time frame: 3 months after implantation

    IOL glistening observation

  5. PCO

    Time frame: 3 months after implantation

    Posterior Capsular Opacification observation

  6. Satisfaction questionnaire

    Time frame: 3 months after implantation

    Satisfaction questionnaire

  7. AE

    Time frame: 3 months after implantation

    Signs of inflammation and AEs

Sponsors and collaborators

Lead sponsor

ICARES Medicus, Inc.

Industry

Collaborators

  • AST Products, Inc.

Registry information

Official study title

Safety and Efficacy of the Bi-Aspheric Monofocal Intraocular Lens

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Apr 24, 2024
Registry last updated
Apr 20, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.